2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163: 608-619. PMID: 35679950, DOI: 10.1053/j.gastro.2022.05.055.Peer-Reviewed Original ResearchConceptsEradication rateHelicobacter pylori infectionTriple therapyDual therapyPylori infectionProton pump inhibitor-based triple therapyTreatment-emergent adverse eventsInhibitor-based triple therapyPotassium-competitive acid blockerEfficacy of vonoprazanH pylori eradicationPhase 3 trialOverall study populationAmoxicillin-resistant strainsClarithromycin-resistant strainsH pylori infectionTreatment-naïve adultsPylori eradicationAdverse eventsSecondary outcomesPrimary outcomeStandard treatmentClinical trialsStudy populationAcid blocker
2019
Management of acute upper gastrointestinal bleeding
Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. The BMJ 2019, 364: l536. PMID: 30910853, DOI: 10.1136/bmj.l536.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Bacterial AgentsBlood TransfusionDisease ManagementEndoscopy, GastrointestinalEsophageal and Gastric VaricesGastrointestinal HemorrhageHumansLiver CirrhosisPortasystemic Shunt, Transjugular IntrahepaticPractice Guidelines as TopicProton Pump InhibitorsResuscitationSeverity of Illness IndexConceptsUpper gastrointestinal bleedingProton pump inhibitorsVariceal bleedingUlcer bleedingGastrointestinal bleedingEndoscopic therapyVasoactive drugsPump inhibitorsHigh-dose proton pump inhibitorsAcute upper gastrointestinal bleedingDose proton pump inhibitorsTransjugular intrahepatic portosystemic shuntNon-variceal bleedingRecurrent ulcer bleedingRecurrent variceal bleedingRed cell transfusionCommon medical emergencyIntrahepatic portosystemic shuntEarly endoscopyCell transfusionHemodynamic instabilityHemoglobin thresholdEndoscopic treatmentIntravenous fluidsPortosystemic shunt
2016
Upper Gastrointestinal Bleeding Due to a Peptic Ulcer
Laine L. Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. New England Journal Of Medicine 2016, 374: 2367-2376. PMID: 27305194, DOI: 10.1056/nejmcp1514257.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
2002
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial
Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Alimentary Pharmacology & Therapeutics 2002, 16: 1143-1148. PMID: 12030957, DOI: 10.1046/j.1365-2036.2002.01267.x.Peer-Reviewed Original ResearchMeSH Keywords2-PyridinylmethylsulfinylbenzimidazolesAdultAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsClarithromycinDrug Therapy, CombinationDyspepsiaFemaleGastroesophageal RefluxHelicobacter InfectionsHumansLansoprazoleMaleMiddle AgedOmeprazolePenicillinsProspective StudiesQuality of LifeUreaConceptsGastro-oesophageal reflux diseaseQuality of lifeH. pylori therapyPylori therapyReflux diseaseH. pyloriSymptomatic gastro-oesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyPopulation of patientsEnd of therapyUrea breath testReflux symptomsPylori eradicationTriple therapyProspective trialEndoscopic biopsyPrimary complaintProspective studyLife QuestionnaireBreath testPatientsTherapyMonthsSymptoms
2001
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals Of Internal Medicine 2001, 134: 361-9. PMID: 11242496, DOI: 10.7326/0003-4819-134-5-200103060-00008.Peer-Reviewed Original ResearchConceptsH. pylori eradication therapyNonulcer dyspepsiaPylori eradication therapyEradication therapyControl therapyOdds ratioH. pyloriHelicobacter pyloriDefinition of dyspepsiaDuplicate data extractionEnd of therapyH. pylori infectionAnalysis of trialsPylori infectionCombination therapyMethodologic qualityTreatment successDyspepsiaPersistent infectionReference listsTherapyPatientsStudy designPrimary investigatorPylori
2000
Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori
Laine L, Sugg J, Suchower L, Neil G. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. Gastrointestinal Endoscopy 2000, 51: 664-669. PMID: 10840297, DOI: 10.1067/mge.2000.105776.Peer-Reviewed Original ResearchConceptsTriple therapyH pylori infectionBody biopsyAntral biopsiesHistologic examinationPylori infectionBiopsy testsDiagnostic yieldProton pump inhibitor-based triple therapyMulticenter double-blind trialInhibitor-based triple therapyDouble-blind trialPost-treatment sensitivityTriple therapy groupDual antibiotic therapyH pylori statusRapid urease testEndoscopic biopsy testsPost-treatment diagnosisHelicobacter pylori diagnosisPretreatment sensitivityEradication therapyUntreated patientsAntibiotic therapyDual therapy
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsHelicobacter pylori and peptic ulcer disease
Laine L, Fendrick A. Helicobacter pylori and peptic ulcer disease. Postgraduate Medicine 1998, 103: 231-243. PMID: 9519040, DOI: 10.3810/pgm.1998.03.423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Bacterial AgentsAnti-Ulcer AgentsClarithromycinDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansPeptic UlcerConceptsPeptic ulcer diseaseUlcer diseaseAppropriate antimicrobial therapyPrimary care physiciansCost of careEffective regimensCare physiciansClinical outcomesH pyloriSuccessful treatmentAntimicrobial therapyPatient complianceHelicobacter pyloriImportance of identifyingDiseaseInfectionPyloriTreatmentRegimenRegimensPatientsTherapyPhysiciansCare